Use of Mesenchymal Stem Cells in Pre-term Patients With Bronchopulmonary Dysplasia. - Trial NCT06270199
Access comprehensive clinical trial information for NCT06270199 through Pure Global AI's free database. This Phase 2 trial is sponsored by Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal and is currently Recruiting. The study focuses on Bronchopulmonary Dysplasia. Target enrollment is 75 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Timeline & Enrollment
Phase 2
Jan 11, 2024
Dec 01, 2026
Primary Outcome
Security of MSC therapy in very low birth weight preterm babies at risk of developing bronchopulmonary dysplasia,feasibility variable
Summary
Bronchopulmonary dysplasia (BPD) is a disease that affects preterm newborn patients,
 preventing their lungs from developing properly. Allogeneic fetal stem mesenchymal cells from
 umbilical cord could reduce the prevalence of BPD in this patients.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06270199
Non-Device Trial